Intergroup-led trials now permanently closed Wednesday, April 11, 2018 There are three intergroup-led trials which have now been deemed permanently closed/terminated by their respective lead group. If you have any questions regarding the trial closure please contact:Christine Bertrim. Data submission and REB approval for the following trials is no longer required: CRC5 (80405): A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum Disease site: Gastrointestinal Records retention: 2043-Mar-19 MAC4C (ANZ0701): Investigating Cognitive Function For Patients Participating In The SOFT Trial In Selected Centers Disease site: Breast Records retention: 2043-Mar-19 MA24 (B016348): A Randomized Three-Arm Multi-Centre Comparison of 1 Year and 2 Years of Herceptin versus no Herceptin in Women With HER2-positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy Disease site: Breast Records retention: 2043-Mar-19
